Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
I-Cell Disease (Mucolipidosis II) is a rare, severe, inherited metabolic disorder. It is a lysosomal storage disease characterized by the failure of cells to transport specific enzymes, leading to the buildup of large, undigested molecules within the cell structures.
read more about i cell disease mucolipidosis ii ...The cause is a genetic defect in the GNPTA gene. This gene defect prevents the body from correctly labeling specific digestive enzymes (lysosomal enzymes) with a mannose-6-phosphate marker. Without this marker, the enzymes are secreted out of the cell instead of being delivered to the cell's "recycling center" (the lysosome). This failure causes large, complex sugar molecules to accumulate inside the cell, leading to widespread cellular dysfunction and structural damage throughout the body's connective tissues.
Symptoms define a severe, rapid decline in physical and cognitive function, often starting in infancy. Infants present with coarse facial features, severe skeletal abnormalities, heart defects, and joint stiffness. Development is profoundly delayed, and children often lose acquired motor skills. The severe nature of the disease significantly shortens the lifespan, with most children not surviving beyond early childhood.
I-Cell Disease severely impacts vision. The buildup of undigested material affects the eye's structure, causing severe corneal clouding (haze) and retinal degeneration. The corneal clouding is often so dense that it requires a corneal transplant (keratoplasty) to restore vision. Patients also suffer from eye misalignment and limited eye movement.
Diagnosis is often made shortly after birth through newborn screening. Confirmation involves blood and urine tests to measure elevated porphyrin precursors. Genetic testing is then used to identify the specific gene mutation, which is central to accurate prognosis and effective family counseling.
Necessary management strategies focus on supportive care and physical therapy. While there is no cure, aggressive physical therapy is used to address joint stiffness. Experimental treatments, such as bone marrow or enzyme replacement therapy, are sometimes attempted to slow the disease's progressive neurological and structural damage.
No, the disorder is severe, progressive, and not curable. Management is mainly supportive.
Yes, the disorder causes profound intellectual and developmental disabilities.
Yes, lysosomal storage disorders are often included in expanded newborn screening panels.
Consult a geneticist for symptoms of coarse facial features and joint stiffness in an infant. I-Cell disease causes progressive "Corneal Clouding." Regular ophthalmic monitoring is required to manage light sensitivity and assess if clouding is impacting early development.
NORD. I-Cell Disease (rarediseases.org). 2024.
AAO. Mucolipidosis II (I-cell Disease) (aao.org). 2024.
Mayo Clinic. Lysosomal Storage Diseases (mayoclinic.org). 2024.
StatPearls. Mucolipidoses (ncbi.nlm.nih.gov). 2024.